Seprase; an Overview of an Important Matrix Serine Protease

Total Page:16

File Type:pdf, Size:1020Kb

Seprase; an Overview of an Important Matrix Serine Protease Seprase; an overview of an important matrix serine protease Pamela O’Brien a *and Brendan F. O’Connor a b a School of Biotechnology, Dublin City University, Dublin 9, Ireland. b Centre for BioAnalytical Sciences, Dublin City University, Dublin 9, Ireland. * CORRESPONDENCE * Corresponding author for proofs: Pamela O’Brien, School Of Biotechnology, Dublin City University, Dublin 9, Ireland. Email address: [email protected] Phone: +353-1-7005908 Fax: +353-1-7005412 KEYWORDS (6) Seprase; Fibroblast Activation Protein alpha; Serine peptidase; Antiplasmin Cleaving Enzyme; Serine Integral Membrane Protein ABBREVIATIONS AEBSF, 4-(2-aminoethyl)-benzenesulfonyl fluoride; AFC, 7-amino-4- trifluoromethylcoumarin; AMC, 7-amino-4-methylcoumarin; APSF, 4-amidino phenylsulfonyl fluoride; DABCYL, 4-(4-dimethylaminophenylazo)benzoyl; DFP, Diisopropyl fluorophosphates; DPPIV, Dipeptidyl peptidase IV; DTT, Dithiothreitol; ECM, Extracellular matrix; EDANS, 5-[(2-aminoethyl)amino]-naphthalene-1-sulfonic acid; EDTA, Ethylenediaminetetra acetic acid; FGF-2, Fibroblast growth factor-2; GBase, Guanidinobutyrase; MMP, Matrix metallo-proteinase; mAb, monoclonal antibody; NEM, N-ethylmaleimide; PMSF, Phenylmethylsulphonyl fluoride; POP, Prolyl Oligopeptidase; SIMP, Serine Integral Membrane Protein; uPA, Urokinase plasminogen activator - 1 - Abstract Seprase or Fibroblast activation protein (FAP) is an integral membrane serine peptidase, which has been shown to have gelatinase activity. Seprase has a dual function in tumour progression. The proteolytic activity of Seprase has been shown to promote cell invasiveness towards the ECM and also to support tumour growth and proliferation. Seprase appears to act as a proteolytically active 170-kDa dimer, consisting of two 97-kDa subunits. It is a member of the group type II integral serine proteases, which include dipeptidyl peptidase IV (DPPIV/CD26) and related type II trans-membrane prolyl serine peptidases, which exert their mechanisms of action on the cell surface. DPPIV and Seprase exhibit multiple functions due to their abilities to form complexes with each other and to interact with other membrane-associated molecules. Localization of these protease complexes at cell surface protrusions, called invadopodia, may have a prominent role in processing soluble factors and in the degradation of extracellular matrix components that are essential to the cellular migration and matrix invasion that occur during tumour invasion, metastasis and angiogenesis. - 2 - 1. Introduction Wound healing and tumour development are dynamic progressive processes that involve the interaction of several tissue types and have many mechanistic similarities. The composition of tumour stroma markedly resembles that of wound granulation tissue, although a distinguishing feature of the tumour stroma is the absence of platelets and a lower density of inflammatory cells [1]. In cancer, these changes in the stroma drive invasion and metastasis, the hallmarks of malignancy (Fig. 1.). Tumour cells can produce many of the same growth factors that activate the adjacent stromal tissues as in wounding or fibrosis. Activated fibroblasts and infiltrating immune cells (macrophages) secrete proteases (MMPs) and cytokines such as Fibroblast Growth Factor-2 (FGF-2). These factors potentiate tumour growth, stimulate angiogenesis and induce fibroblasts to undergo differentiation into myofibroblasts and into smooth muscle [2]. Cell surface proteases play an important role in facilitating cell invasion into the extracellular matrix. Proteases associate at plasma membrane protrusions, called invadopodia, which contact and dissolve the matrix. Invadopodia degrade a variety of immobilised substrates including fibronectin, laminin and type I collagen [3]. Integral membrane proteases may contribute significantly to ECM degradation by metastatic cells by virtue of their localisation at invadopodia which are in contact with the ECM. Integral membrane proteases can be defined as a group of cell surface glycoproteins that contain extracellular domains of either metallo- or serine-proteases, a transmembrane domain and a short cytoplasmic tail. Examples of such transmembrane glycoproteins include meprin, matrix metalloproteinase, DPPIV, - 3 - fibroblast activation protein α (FAPα) / Seprase and GBase. Abundant expression of these enzymes is associated with poor prognosis [4]. This review will take a detailed look at the serine protease Seprase (surface expressed protease) or Fibroblast Activation Protein α (FAPα), a 170kDa integral membrane gelatinase, which belongs to the S9b peptidase family [5, 6]. FAPα, formerly known as F19 Cell Surface Antigen, is an inducible cell surface glycoprotein that was originally identified in 1986 in cultured fibroblasts using the monoclonal antibody (mAb) F19 [7-9][7, 8]. In the early years using the mAb F19, malignant epithelial cancers such as breast, lung, colon and ovarian were found to be F19- . In 1994, the F19 Cell Surface Antigen was named Fibroblast Activation Protein α (FAPα) . In 1990 a 170kDa gelatinase was identified in the human malignant melanoma cell line LOX . The 170kDa membrane-bound protease was found to be associated with the expression of invasiveness by human malignant melanoma cells. In 1994, the 170kDa gelatinase was named Seprase . Seprase was originally identified as a glycoprotein peptidase selectively expressed on the surface of invadopodia and was isolated from a human malignant melanoma cell line LOX [3, 12][9]. The expression of Seprase correlates with the invasiveness of human melanoma and carcinoma cells [12][9]. Using anti-Seprase mAbs, Seprase was seen to be expressed in stromal fibroblasts of more than 90% of all epithelial tumours including lung, colorectal and breast carcinomas (primary and metastatic) . Molecular cloning of both FAPα and Seprase revealed that they are the same cell surface serine protease which is found on chromosome 2q23 [12-16][9-13]. The fact that FAPα and Seprase are the same protease means that the above immunohistochemistry results contradict each other. The reason for the differing results is due to the different monoclonal antibodies - 4 - recognising different parts of the serine protease. For the clarity of this review, the protease is referred to as Seprase throughout. 2. Classification of Seprase / Fibroblast Activation Protein alpha (FAPα) Seprase (EC 3.4.21.B28) belongs to the small family of serine integral membrane peptidases (SIMPs). These peptidases are inducible, specific for proline-containing peptides and macromolecules and active on the cell surface [15]. Post proline peptidases modify bioactive peptides and change their cellular functions. This class of peptidases have important roles in cancer [14, 15, 17-19]. This group of enzymes also includes prolyl endopeptidase, dipeptidyl peptidase 8 and dipeptidyl peptidase IV-β [19]. However, the best studied of this class of enzymes is dipeptidyl peptidase IV (DPPIV or CD26) (EC 3.4.14.5) [19]. Studies have shown the importance of DPPIV in regulating tumour cell behaviour and function [20]. Seprase shows up to 52% homology to DPPIV, both being members of the S9b peptidase family [21]. Seprase is, therefore, a member of the DPPIV-like gene family [5] grouped in the subfamily S9b of the peptidase family S9 (prolyl oligopeptidase family), clan SC [6]. Even though all SIMP members are known to cleave prolyl peptide (Pro-Xaa) bonds there are conflicting reports on possible dipeptidyl peptidase activity associated with Seprase but its main distinguishing feature is its gelatinase activity [22, 23]. An early report had suggested that DPPIV had gelatinase activity [24]. However, more recent reports suggest otherwise [22, 23]. The exact nature of the physiological roles Seprase plays are only beginning to be understood but insights into potential functions of Seprase can be obtained from the vast amount of work done on DPPIV. - 5 - - 6 - 3. Structure and Biochemical Aspects Active Seprase is a 170kDa homodimer that contains two N-glycosylated 97kDa subunits. The 760 amino acid Seprase protein (GenBank GI 1888316) is a type II integral membrane protein with a large C-terminal extracellular domain. Seprase has been shown to shed from the cell surface and recent studies by our group have identified a serum form of the protease [25][22]. A second group has recently identified the soluble form of Antiplasmin Cleaving Enzyme (APCE) as Seprase [26][23]. The Seprase monomer has 5 potential N-glycosylation sites, 13 cysteine residues, 3 segments that correspond to highly conserved catalytic domains of serine proteases, a hydrophobic transmembrane segment and a short cytoplasmic tail (6 amino acids) (Fig. 1. ref [14][11]). The crystal structure of the extracellular domain of Seprase has recently been resolved (Fig. 2.) [27][24]. This has provided valuable information on the substrate specificity of Seprase (discussed further in this Section and also in Section 7.). Each subunit contains topologically distinct domains: the β-propeller (residues 54- 492) and the α/β-hydrolase domain (residues 27-53 and 493-760) (Fig. 2.). The catalytic triad is located at the interface of the β-propeller and the α/β-hydrolase domain. The arrangement of the catalytic triad in the order nucleophile-acid-base is a characteristic of the α/β hydrolase domain [28][25]. This domain features mostly parallel β-sheets connected by α-helices on either surface of the sheet (Fig. 3A.). The sheets are twisted and radially arranged around their ventral
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0346364 A1 BRUNS Et Al
    US 2016.0346364A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0346364 A1 BRUNS et al. (43) Pub. Date: Dec. 1, 2016 (54) MEDICAMENT AND METHOD FOR (52) U.S. Cl. TREATING INNATE IMMUNE RESPONSE CPC ........... A61K 38/488 (2013.01); A61K 38/482 DISEASES (2013.01); C12Y 304/23019 (2013.01); C12Y 304/21026 (2013.01); C12Y 304/23018 (71) Applicant: DSM IPASSETS B.V., Heerlen (NL) (2013.01); A61K 9/0053 (2013.01); C12N 9/62 (2013.01); A23L 29/06 (2016.08); A2ID 8/042 (72) Inventors: Maaike Johanna BRUINS, Kaiseraugst (2013.01); A23L 5/25 (2016.08); A23V (CH); Luppo EDENS, Kaiseraugst 2002/00 (2013.01) (CH); Lenneke NAN, Kaiseraugst (CH) (57) ABSTRACT (21) Appl. No.: 15/101,630 This invention relates to a medicament or a dietary Supple (22) PCT Filed: Dec. 11, 2014 ment comprising the Aspergillus niger aspergilloglutamic peptidase that is capable of hydrolyzing plant food allergens, (86). PCT No.: PCT/EP2014/077355 and more particularly, alpha-amylase/trypsin inhibitors, thereby treating diseases due to an innate immune response S 371 (c)(1), in humans, and/or allowing to delay the onset of said (2) Date: Jun. 3, 2016 diseases. The present invention relates to the discovery that (30) Foreign Application Priority Data the Aspergillus niger aspergilloglutamic peptidase is capable of hydrolyzing alpha-amylase/trypsin inhibitors that are Dec. 11, 2013 (EP) .................................. 13196580.8 present in wheat and related cereals said inhibitors being strong inducers of innate immune response. Furthermore, Publication Classification the present invention relates to a method for hydrolyzing alpha-amylase/trypsin inhibitors comprising incubating a (51) Int.
    [Show full text]
  • Clinical Study High Complement Factor I Activity in the Plasma of Children with Autism Spectrum Disorders
    Hindawi Publishing Corporation Autism Research and Treatment Volume 2012, Article ID 868576, 6 pages doi:10.1155/2012/868576 Clinical Study High Complement Factor I Activity in the Plasma of Children with Autism Spectrum Disorders Naghi Momeni,1 Lars Brudin,2 Fatemeh Behnia,3 Berit Nordstrom,¨ 4 Ali Yosefi-Oudarji,5 Bengt Sivberg,4 Mohammad T. Joghataei,5 and Bengt L. Persson1 1 School of Natural Sciences, Linnaeus University, 39182 Kalmar, Sweden 2 Department of Clinical Physiology, Kalmar County Hospital, 39185 Kalmar, Sweden 3 Department of Occupational Therapy, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran 4 Department of Health Sciences, Autism Research, Faculty of Medicine, Lund University, Box 157, 22100 Lund, Sweden 5 Cellular and Molecular Research Centre, Tehran University of Medical Sciences (TUMS), Tehran, Iran Correspondence should be addressed to Bengt Sivberg, [email protected] Received 17 June 2011; Revised 22 August 2011; Accepted 22 August 2011 Academic Editor: Judy Van de Water Copyright © 2012 Naghi Momeni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Autism spectrum disorders (ASDs) are neurodevelopmental and behavioural syndromes affecting social orientation, behaviour, and communication that can be classified as developmental disorders. ASD is also associated with immune system abnormality. Im- mune system abnormalities may be caused partly by complement system factor I deficiency. Complement factor I is a serine pro- tease present in human plasma that is involved in the degradation of complement protein C3b, which is a major opsonin of the complement system.
    [Show full text]
  • Mouse Prolyl Endopeptidase / PREP Protein (His Tag)
    Mouse Prolyl endopeptidase / PREP Protein (His Tag) Catalog Number: 50288-M07B General Information SDS-PAGE: Gene Name Synonym: AI047692; AI450383; D10Wsu136e; PEP; Pop Protein Construction: A DNA sequence encoding the mature form of mouse PREP (Q9QUR6) (Leu2-Gln710) was expressed, with a polyhistidine tag at the N-terminus. Source: Mouse Expression Host: Baculovirus-Insect Cells QC Testing Purity: > 95 % as determined by SDS-PAGE Endotoxin: Protein Description < 1.0 EU per μg of the protein as determined by the LAL method Prolyl endopeptidase, also known as PREP, belongs to a distinct class of Stability: serine peptidases. It is a large cytosolic enzyme which was first described in the cytosol of rabbit brain as an oligopeptidase. Prolyl endopeptidase ℃ Samples are stable for up to twelve months from date of receipt at -70 degrades the nonapeptide bradykinin at the Pro-Phe bond. It is involved in the maturation and degradation of peptide hormones and neuropeptides His Predicted N terminal: such as alpha-melanocyte-stimulating hormone, luteinizing hormone- Molecular Mass: releasing hormone (LH-RH), thyrotropin-releasing hormone, angiotensin, neurotensin, oxytocin, substance P and vasopressin. Prolyl The recombinant mouse PREP consists of 727 amino acids and predicts a endopeptidase's activity is confined to action on oligopeptides of less than molecular mass of 82.9 KDa. It migrates as an approximately 79-83 KDa 10 kD and it has an absolute requirement for the trans-configuration of the band in SDS-PAGE under reducing conditions. peptide bond preceding proline. It cleaves peptide bonds at the C-terminal side of proline residues. Formulation: References Lyophilized from sterile 20mM Tris, 500mM NaCl, pH 7.4, 10% glycerol, 3mM DTT 1.Oliveira EB, et al.
    [Show full text]
  • Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases
    International Journal of Molecular Sciences Review Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases Peter Goettig Structural Biology Group, Faculty of Molecular Biology, University of Salzburg, Billrothstrasse 11, 5020 Salzburg, Austria; [email protected]; Tel.: +43-662-8044-7283; Fax: +43-662-8044-7209 Academic Editor: Cheorl-Ho Kim Received: 30 July 2016; Accepted: 10 November 2016; Published: 25 November 2016 Abstract: Posttranslational modifications are an important feature of most proteases in higher organisms, such as the conversion of inactive zymogens into active proteases. To date, little information is available on the role of glycosylation and functional implications for secreted proteases. Besides a stabilizing effect and protection against proteolysis, several proteases show a significant influence of glycosylation on the catalytic activity. Glycans can alter the substrate recognition, the specificity and binding affinity, as well as the turnover rates. However, there is currently no known general pattern, since glycosylation can have both stimulating and inhibiting effects on activity. Thus, a comparative analysis of individual cases with sufficient enzyme kinetic and structural data is a first approach to describe mechanistic principles that govern the effects of glycosylation on the function of proteases. The understanding of glycan functions becomes highly significant in proteomic and glycomic studies, which demonstrated that cancer-associated proteases, such as kallikrein-related peptidase 3, exhibit strongly altered glycosylation patterns in pathological cases. Such findings can contribute to a variety of future biomedical applications. Keywords: secreted protease; sequon; N-glycosylation; O-glycosylation; core glycan; enzyme kinetics; substrate recognition; flexible loops; Michaelis constant; turnover number 1.
    [Show full text]
  • Reducing Immunoreactivity of Gliadins and Coeliac-Toxic Peptides Using Peptidases from L
    catalysts Article Reducing Immunoreactivity of Gliadins and Coeliac-Toxic Peptides Using Peptidases from L. acidophilus 5e2 and A. niger Bartosz Brzozowski *, Katarzyna Stasiewicz, Mateusz Ostolski and Marek Adamczak Department of Food Biotechnology, Faculty of Food Sciences, University of Warmia and Mazury in Olsztyn, 10-718 Olsztyn, Poland; [email protected] (K.S.); [email protected] (M.O.); [email protected] (M.A.) * Correspondence: [email protected] Received: 21 July 2020; Accepted: 10 August 2020; Published: 11 August 2020 Abstract: Wheat storage proteins and products of their hydrolysis may cause coeliac sprue in genetically predisposed individuals with high expression of main histocompatibility complex HLA-DQ2 or DQ8, since by consuming wheat, they become exposed to proline- (P) and glutamine (Q)-rich gluten. In bread-making, the hydrolysis of gliadins and coeliac-toxic peptides occurs with varied efficiency depending on the fermentation pH and temperature. Degradation of gliadins catalysed by Lactobacillus acidophilus 5e2 peptidases and a commercial prolyl endopeptidase synthesised by A. niger, carried out at pH 4.0 and 37 ◦C, reduces the gliadin concentration over 110-fold and decreases the relative immunoreactivity of the hydrolysate to 0.9% of its initial value. Hydrolysis of coeliac-toxic peptides: LGQQQPFPPQQPY (P1) and PQPQLPYPQPQLP (P2) under the same conditions occurs with the highest efficiency, reaching 99.8 0.0% and 97.5 0.1%, respectively. ± ± The relative immunoreactivity of peptides P1 and P2 was 0.8 0.0% and 3.2 0.0%, respectively. ± ± A mixture of peptidases from L. acidophilus 5e2 and A. niger may be used in wheat sourdough fermentation to reduce the time needed for degradation of proteins and products of their hydrolysis.
    [Show full text]
  • CDH12 Cadherin 12, Type 2 N-Cadherin 2 RPL5 Ribosomal
    5 6 6 5 . 4 2 1 1 1 2 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 A A A A A A A A A A A A A A A A A A A A C C C C C C C C C C C C C C C C C C C C R R R R R R R R R R R R R R R R R R R R B , B B B B B B B B B B B B B B B B B B B , 9 , , , , 4 , , 3 0 , , , , , , , , 6 2 , , 5 , 0 8 6 4 , 7 5 7 0 2 8 9 1 3 3 3 1 1 7 5 0 4 1 4 0 7 1 0 2 0 6 7 8 0 2 5 7 8 0 3 8 5 4 9 0 1 0 8 8 3 5 6 7 4 7 9 5 2 1 1 8 2 2 1 7 9 6 2 1 7 1 1 0 4 5 3 5 8 9 1 0 0 4 2 5 0 8 1 4 1 6 9 0 0 6 3 6 9 1 0 9 0 3 8 1 3 5 6 3 6 0 4 2 6 1 0 1 2 1 9 9 7 9 5 7 1 5 8 9 8 8 2 1 9 9 1 1 1 9 6 9 8 9 7 8 4 5 8 8 6 4 8 1 1 2 8 6 2 7 9 8 3 5 4 3 2 1 7 9 5 3 1 3 2 1 2 9 5 1 1 1 1 1 1 5 9 5 3 2 6 3 4 1 3 1 1 4 1 4 1 7 1 3 4 3 2 7 6 4 2 7 2 1 2 1 5 1 6 3 5 6 1 3 6 4 7 1 6 5 1 1 4 1 6 1 7 6 4 7 e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m
    [Show full text]
  • Table 6. Putative Genes Involved in the Utilization of Carbohydrates in G
    Table 6. Putative genes involved in the utilization of carbohydrates in G. thermodenitrificans NG80-2 genome Carbohydrates* Enzymes Gene ID Glycerol Glycerol Kinase GT1216 Glycerol-3-phosphate dehydrogenase, aerobic GT2089 NAD(P)H-dependent glycerol-3-phosphate dehydrogenase GT2153 Enolase GT3003 2,3-bisphosphoglycerate-independentphosphoglycerate mutase GT3004 Triosephosphate isomerase GT3005 3-phosphoglycerate kinase GT3006 Glyceraldehyde-3-phosphate dehydrogenase GT3007 Phosphoglycerate mutase GT1326 Pyruvate kinase GT2663 L-Arabinose L-arabinose isomerase GT1795 L-ribulokinase GT1796 L-ribulose 5-phosphate 4-epimerase GT1797 D-Ribose Ribokinase GT3174 Transketolase GT1187 Ribose 5-phosphate epimerase GT3316 D-Xylose Xylose kinase GT1756 Xylose isomerase GT1757 D-Galactose Galactokinase GT2086 Galactose-1-phosphate uridyltransferase GT2084 UDP-glucose 4-epimerase GT2085 Carbohydrates* Enzymes Gene ID D-Fructose 1-phosphofructokinase GT1727 Fructose-1,6-bisphosphate aldolase GT1805 Fructose-1,6-bisphosphate aldolase type II GT3331 Triosephosphate isomerase GT3005 D-Mannose Mannnose-6 phospate isomelase GT3398 6-phospho-1-fructokinase GT2664 D-Mannitol Mannitol-1-phosphate dehydrogenase GT1844 N-Acetylglucosamine N-acetylglucosamine-6-phosphate deacetylase GT2205 N-acetylglucosamine-6-phosphate isomerase GT2204 D-Maltose Alpha-1,4-glucosidase GT0528, GT1643 Sucrose Sucrose phosphorylase GT3215 D-Trehalose Alpha-glucosidase GT1643 Glucose kinase GT2381 Inositol Myo-inositol catabolism protein iolC;5-dehydro-2- GT1807 deoxygluconokinase
    [Show full text]
  • An Investigation on Catalysis of Acylaminoacyl Peptidases
    An investigation on catalysis of acylaminoacyl peptidases PhD Thesis András László Kiss Doctorate School of Biology School leader: Prof. Anna Erdei Structural Biochemistry Programme Programme leader: Prof. László Gráf Supervisor: Prof. László Polgár Institute of Enzymology, Biological Research Center, Hungarian Academy of Sciences Budapest 2007 1. Introduction Serine peptidases contain two residues at the active site in addition to the catalytic triad (His, Asp, Ser), which form a cavity called “oxyanion hole” that accommodates the negatively charged oxyanion in the transition state of the catalysis and donate two H- bonds. Enzymes of the prolyl oligopeptidase (POP) family (acylaminoacyl peptidase, prolyl oligopeptidase, dipeptidyl peptidase IV and oligopeptidase B) are extensively studied. These enzymes are larger than classical serine peptidases and are composed of a peptidase domain with an α/β hydrolase fold and a β-propeller domain. POP and oligopeptidase B are monomeric enzymes and endopeptidases, while the exopeptidase acylaminoacyl peptidase and dipeptidyl peptidase IV are tetrameric and dimeric enzymes, respectively. Acylaminoacyl peptidase (AAP) cleaves acylated amino acids from the N-terminus of the N-acylated peptides that plays important role in many biological and disease processes. Human AAP is encoded by the DNF15S2 locus on the short arm of chromosome 3 at the region 21, which suffers deletions in small cell lung carcinomas, and renal carcinomas, resulting in deficiency in the expression of the enzyme. Acylaminoacyl peptidase is also supposed to be involved in the degradation of oxidatively damaged proteins in cells and can be associated with various diseases where damaged proteins aggregate. Its involvement in cataract formation and in the breakdown of immunogenic formylmethionyl-peptides in the digestive tract after bacterial attack was also suggested.
    [Show full text]
  • High-Resolution Mass Spectrometry-Based Approaches for the Detection and Quantification of Peptidase Activity in Plasma
    molecules Article High-Resolution Mass Spectrometry-Based Approaches for the Detection and Quantification of Peptidase Activity in Plasma Elisa Maffioli 1,2 , Zhenze Jiang 3, Simona Nonnis 1,2 , Armando Negri 1,2, Valentina Romeo 1, Christopher B. Lietz 3, Vivian Hook 3,4, Giuseppe Ristagno 5, Giuseppe Baselli 6, Erik B. Kistler 7,8 , Federico Aletti 9, Anthony J. O’Donoghue 3,* and Gabriella Tedeschi 1,2,* 1 Department of Veterinary Medicine, University of Milano, 20133 Milano, Italy; elisa.maffi[email protected] (E.M.); [email protected] (S.N.); [email protected] (A.N.); [email protected] (V.R.) 2 Centre for Nanostructured Materials and Interfaces (CIMAINA), University of Milano, 20133 Milano, Italy 3 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA; [email protected] (Z.J.); [email protected] (C.B.L.); [email protected] (V.H.) 4 Department of Neurosciences, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA 5 Department of Pathophysiology and Transplantation, University of Milan, 20133 Milan, Italy; [email protected] 6 Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, 20133 Milan, Italy; [email protected] 7 Department of Anesthesiology & Critical Care, University of California San Diego, La Jolla, CA 92093, USA; [email protected] 8 Department of Anesthesiology & Critical Care, VA San Diego HealthCare System, San Diego, CA 92161, USA 9 Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA; [email protected] * Correspondence: [email protected] (A.J.O.); [email protected] (G.T.); Tel.: +1-8585345360 (A.J.O.); +39-02-50318127 (G.T.) Academic Editor: Paolo Iadarola Received: 28 July 2020; Accepted: 4 September 2020; Published: 6 September 2020 Abstract: Proteomic technologies have identified 234 peptidases in plasma but little quantitative information about the proteolytic activity has been uncovered.
    [Show full text]
  • Supplementary Table 1: List of the 316 Genes Regulated During Hyperglycemic Euinsulinemic Clamp in Skeletal Muscle
    Supplementary Table 1: List of the 316 genes regulated during hyperglycemic euinsulinemic clamp in skeletal muscle. UGCluster Name Symbol Fold Change Cytoband Response to stress Hs.517581 Heme oxygenase (decycling) 1 HMOX1 3.80 22q12 Hs.374950 Metallothionein 1X MT1X 2.20 16q13 Hs.460867 Metallothionein 1B (functional) MT1B 1.70 16q13 Hs.148778 Oxidation resistance 1 OXR1 1.60 8q23 Hs.513626 Metallothionein 1F (functional) MT1F 1.47 16q13 Hs.534330 Metallothionein 2A MT2A 1.45 16q13 Hs.438462 Metallothionein 1H MT1H 1.42 16q13 Hs.523836 Glutathione S-transferase pi GSTP1 -1.74 11q13 Hs.459952 Stannin SNN -1.92 16p13 Immune response, cytokines & related Hs.478275 TNF (ligand) superfamily, member 10 (TRAIL) TNFSF10 1.58 3q26 Hs.278573 CD59 antigen p18-20 (protectin) CD59 1.49 11p13 Hs.534847 Complement component 4B, telomeric C4A 1.47 6p21.3 Hs.535668 Immunoglobulin lambda variable 6-57 IGLV6-57 1.40 22q11.2 Hs.529846 Calcium modulating ligand CAMLG -1.40 5q23 Hs.193516 B-cell CLL/lymphoma 10 BCL10 -1.40 1p22 Hs.840 Indoleamine-pyrrole 2,3 dioxygenase INDO -1.40 8p12-p11 Hs.201083 Mal, T-cell differentiation protein 2 MAL2 -1.44 Hs.522805 CD99 antigen-like 2 CD99L2 -1.45 Xq28 Hs.50002 Chemokine (C-C motif) ligand 19 CCL19 -1.45 9p13 Hs.350268 Interferon regulatory factor 2 binding protein 2 IRF2BP2 -1.47 1q42.3 Hs.567249 Contactin 1 CNTN1 -1.47 12q11-q12 Hs.132807 MHC class I mRNA fragment 3.8-1 3.8-1 -1.48 6p21.3 Hs.416925 Carcinoembryonic antigen-related cell adhesion molecule 19 CEACAM19 -1.49 19q13.31 Hs.89546 Selectin E (endothelial
    [Show full text]
  • Prolyl Endopeptidase from Aspergillus Niger Expressing A
    Annex 3 FORM ON WHICH INFORMATION ON THE COMPOUND TO BE EVALUATED BY JECFA IS PROVIDED In completing this form, only brief information is required. The form may be retyped if more space is needed under any one heading provided that the general format is maintained. Name of Compound(s): Acid prolyl endopeptidase from a genetically modified strain of Aspergillus niger Question(s) to be answered by JECFA Safety evaluation when used as processing aid. (kindly provide a brief justification of the request in case of re-evaluations) 1. Proposal for inclusion submitted by: Ministry of Health, Welfare and Sport Nutrition, Health Protection and Prevention Department Parnassusplein 5 2511 VX The Hague P.O. box 20350 2500 EJ The Hague The Netherlands Tel: +31 703407132 2. Name of compound; trade name(s); chemical name(s): Name of compound : Acid prolyl endopeptidase from a genetically modified strain of Aspergillus niger Trade names : BREWERS CLAREX®, MAXIPRO PSP Chemical name : Acid prolyl endopeptidase (EC 3.4.21.xx1) 3. Names and addresses of basic producers: DSM Food Specialties 15 Rue des Comtesses PO Box 239 59472 Seclin Cédex France Tel: 33 320964545 Fax: 33 320964500 4. Has the manufacturer made a commitment to provide data? Yes. 5. Identification of the manufacturer that will be providing data (Please indicate contact person): Dr Jack Reuvers 1 The name proline endopeptidase is also a synonym of prolyl oligopeptidase, EC (IUBMB) number 3.4.21.26. However, in contrast to oligopeptidases, the enzyme also acts on proteins (Edens et al., 2005; Kubota et al., 2005; Takahashi, 2013).
    [Show full text]
  • And Exopeptidases in a Processing Enzyme System: Activation
    Proc. Nail. Acad. Sci. USA Vol. 85, pp. 5468-5472, August 1988 Biochemistry Relationship between endo- and exopeptidases in a processing enzyme system: Activation of an endoprotease by the aminopeptidase B-like activity in somatostatin-28 convertase (brain cortex/basic amino acid pairs/peptide substrates/protease inhibitors/prohormone maturation) SOPHIE GOMEZ, PABLO GLUSCHANKOF, AGNES LEPAGE, AND PAUL COHEN Groupe de Neurobiochimie Cellulaire et Moldculaire, Universitd Pierre et Marie Curie, Unitd Associde 554 au Centre National de la Recherche Scientifique, 96 boulevard Raspail, 75006 Paris, France Communicated by I. Robert Lehman, April 8, 1988 (receivedfor review December 15, 1987) ABSTRACT The somatostatin-28 convertase activity in- somatostatin-14 and the amino-terminal dodecapeptide so- volved in vitro in the processing of somatostatin-28 into the matostatin-28-(1-12) (16). neuropeptides somatostatin-28-(1-12) and somatostatin-14 is We have described an endoprotease that cleaves the composed of an endoprotease and a basic aminopeptidase. We peptide bond on the amino side ofthe Arg-Lys doublet in the report herein on the purification to apparent homogeneity of somatostatin-28 sequence (17, 18), releasing the somato- these two constituents and on their functional interrelationship. statin-28-(1-12) fragment and [Arg-2,Lys-1]somatostatin-14. In particular we observed that after various physicochemical The released [Arg-2,Lys-']somatostatin-14 is further proc- treatments, the 90-kDa endoprotease activity was recovered essed by an aminopeptidase B-like activity (18, 19) that is also both at this molecular mass and as a 45-kDa entity. Moreover, present in the preparation. We report herein the purification the production of [Arg2,LysJllsomatostatin-14 from somato- to apparent homogeneity ofthese two activities.
    [Show full text]